Ticagrelor-Induced Prolongation of the QTc Interval

BACKGROUND: Ticagrelor has been accepted as a class I antiplatelet agent in patients undergoing percutaneous coronary angioplasty (PTCA). There have been cases reported on ticagrelor being associated with various cardiac conduction defects. But there is no evidence of QTc prolongation associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Avik, Najmi, Ahmad, Khandelwal, Gaurav, Sadasivam, Balakrishnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881594/
https://www.ncbi.nlm.nih.gov/pubmed/31827937
http://dx.doi.org/10.1155/2019/5984847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881594/
https://www.ncbi.nlm.nih.gov/pubmed/31827937
http://dx.doi.org/10.1155/2019/5984847

Ejemplares similares